Twist Bioscience (TWST) – Research Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Twist Bioscience (NASDAQ: TWST):

• 12/29/2025 – Twist Bioscience had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Twist Bioscience had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Twist Bioscience had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Twist Bioscience had its price target raised by analysts at Barclays PLC from $37.00 to $39.00. They now have an “overweight” rating on the stock.
• 12/8/2025 – Twist Bioscience had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Twist Bioscience had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Twist Bioscience had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – Twist Bioscience had its price target lowered by analysts at Barclays PLC from $40.00 to $37.00. They now have an “overweight” rating on the stock.
• 11/13/2025 – Twist Bioscience had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/3/2025 – Twist Bioscience is now covered by analysts at Stephens. They set an “overweight” rating and a $41.00 price target on the stock.
• 11/3/2025 – Twist Bioscience is now covered by analysts at Stephens. They set an “overweight” rating and a $41.00 price target on the stock.

Insider Activity

In related news, CAO Robert F. Werner sold 1,016 shares of Twist Bioscience stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $31.44, for a total value of $31,943.04. Following the transaction, the chief accounting officer directly owned 51,030 shares in the company, valued at $1,604,383.20. This trade represents a 1.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Paula Green sold 1,084 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $32.08, for a total transaction of $34,774.72. Following the completion of the transaction, the senior vice president directly owned 142,187 shares in the company, valued at $4,561,358.96. This represents a 0.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 119,080 shares of company stock worth $3,797,825 over the last 90 days. 3.01% of the stock is owned by corporate insiders.

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.